1. Home
  2. TLSA vs CCCC Comparison

TLSA vs CCCC Comparison

Compare TLSA & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.46

Market Cap

192.1M

Sector

Health Care

ML Signal

HOLD

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$2.71

Market Cap

185.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TLSA
CCCC
Founded
2013
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
192.1M
185.1M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
TLSA
CCCC
Price
$1.46
$2.71
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$11.80
AVG Volume (30 Days)
139.1K
1.5M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.45
EPS
N/A
N/A
Revenue
N/A
$35,947,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.02
52 Week Low
$0.73
$1.09
52 Week High
$2.60
$3.64

Technical Indicators

Market Signals
Indicator
TLSA
CCCC
Relative Strength Index (RSI) 51.28 72.18
Support Level $1.30 $2.26
Resistance Level $1.50 $2.85
Average True Range (ATR) 0.10 0.20
MACD 0.01 0.11
Stochastic Oscillator 85.71 78.26

Price Performance

Historical Comparison
TLSA
CCCC

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Share on Social Networks: